Autolus Therapeutics plc Files 8-K/A Amendment

TL;DR

Autolus filed an amendment to its 8-K, updating financial condition details.

AI Summary

Autolus Therapeutics plc filed an 8-K/A on March 15, 2024, to amend a previous filing. The amendment pertains to the 'Results of Operations and Financial Condition' as of March 14, 2024. The company, incorporated in England and Wales, is based in London.

Why It Matters

This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information regarding the company's financial condition.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or significant financial changes.

Key Players & Entities

• Autolus Therapeutics plc (company) — Registrant
• March 14, 2024 (date) — Date of earliest event reported
• March 15, 2024 (date) — Date of report
• England and Wales (jurisdiction) — State or other jurisdiction of incorporation or organization
• London (location) — Address of principal executive offices

FAQ

From the Filing

0001730463-24-000029.txt : 20240315 0001730463-24-000029.hdr.sgml : 20240315 20240315162126 ACCESSION NUMBER: 0001730463-24-000029 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20240314 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 24755102 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K/A 1 autl-20240314.htm 8-K/A autl-20240314 0001730463 FALSE 0001730463 2024-03-14 2024-03-14 0001730463 sic:Z8880 2024-03-14 2024-03-14 0001730463 us-gaap:CommonClassAMember 2024-03-14 2024-03-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) The Mediaworks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices)(Zip Code) (44) 20 3829 6230 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Select Market Ordinary shares, nominal value $0.000042 per share* * The Nasdaq Stock Market LLC * * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Explanatory Note This Amendment No. 1 to the Current Report on Form 8-K amends Item 2.02 of the Current Report on Form 8-K filed by Autolus Therapeutics plc (the “ Company ”) on March 14, 2024 (the “ Original Form 8-K ”) solely to furnish the transcript of its conference call held on March 14, 2024 for the reason descri